Thimet oligopeptidase as a potential CSF biomarker for Alzheimer's disease: A cross-platform validation study.

ABSTRACT:

Introduction

Our previous antibody-based cerebrospinal fluid (CSF) proteomics study showed that Thimet oligopeptidase (THOP1), an amyloid beta (Aβ) neuropeptidase, was increased in mild cognitive impairment with amyloid pathology (MCI-Aβ+) and Alzheimer's disease (AD) dementia compared with controls and dementia with Lewy bodies (DLB), highlighting the potential of CSF THOP1 as an early specific biomarker for AD. We aimed to develop THOP1 immunoassays for large-scale analysis and validate our proteomics findings in two independent cohorts.

Methods

We developed in-house CSF THOP1 immunoassays on automated Ella and Simoa platforms. The performance of the different assays were compared using Passing-Bablok regression analysis in a subset of CSF samples from the discovery cohort

SUBMITTER: Hok-A-Hin YS 

PROVIDER: S-EPMC10369371 | biostudies-literature | 2023 Jul-Sep

REPOSITORIES: biostudies-literature